$ACHV News

Achieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission

ACHV: CEO Enlists New Commercialization Team

Achieve Life Sciences Inc (ACHV) Q1 2026 Earnings Call Highlights: Strategic Financing and ...

Achieve Life Sciences, Inc. Q1 2026 Earnings Call Summary

Achieve Life Sciences Q1 Earnings Call Highlights

ACHV Stock Surges After Achieve Life Sciences Reports Market-Beating Q1 2026 Earnings

Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Achieve Life Sciences Reports Q1 2026 Results: Full Earnings Call Transcript

Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026

ACHV: Change of Command Brings Material Funding

Canaccord Genuity Initiates Coverage On Achieve Life Sciences with Buy Rating, Announces Price Target of $13

Achieve Life Sciences Launches Up to $354 Million Private Placement; Names Andrew Goldberg CEO; Shares Rise

Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

Achieve Life Sciences Announces Up to $354 Million Private Placement

Achieve Life Sciences shares are trading higher after the company announced it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities for gross proceeds up to approximately $354 million. Also, HC Wainwright & Co. reiterated its Buy rating and maintained a $12 price target.

Achieve Life Sciences Appoints Andrew Goldberg As CEO

Achieve Life Sciences Announces $180M Financing Upfront With Up To Additional $174M From Warrants Exercisable Within 20 Days Of FDA Approval

HC Wainwright & Co. Reiterates Buy on Achieve Life Sciences, Maintains $12 Price Target